Treatment-free remission in chronic myeloid leukemia

Matteo Molica, Kiran Naqvi, Jorge E. Cortes, Shilpa Paul, Tapan M. Kadia, Massimo Breccia, Hagop Kantarjian, Elias J. Jabbour

Research output: Contribution to journalArticle

Abstract

Tyrosine kinase inhibitors (TKIs) represent a major breakthrough in the treatment of chronic myeloid leukemia (CML). Thanks to these agents, CML has been transformed from a disease with limited treatment options and a dismal prognosis into a more indolent disease with survival comparable to that of the general population. The need for ongoing TKI therapy remains controversial for several reasons, including cost and toxicity. Studies in CML patients with a sustained deep molecular response have demonstrated that stopping TKI therapy is feasible and safe. Given the heterogeneity of results reported in clinical trials, practice guidelines for optimal patient selection and proper monitoring after discontinuation of TKIs are proposed outside of clinical trials. Current data available show that 40% to 60% of patients who stop therapy relapse; molecular relapses typically occur within 6 months, but nearly all relapsing patients regain response upon reinitiation of the TKI. Several factors that predict for relapse have been investigated. Duration of prior TKI therapy, achievement of deep molecular response, depth of molecular response, prior interferon treatment, and Sokal risk score have been shown to be potential predictors for relapse. Leukemia stem cells that are resistant to TKIs, and that persist despite undetectable BCR/ ABL1 transcript levels, likely are responsible for disease relapse after discontinuation. Efforts geared toward better identification of low levels of BCR/ABL1 transcript using new techniques such as digital polymerase chain reaction, along with eradicating CML clones using combination therapies with agents such as pegylated interferon or venetoclax with TKIs, will hopefully lead to a functional cure of this disease.

Original languageEnglish (US)
Pages (from-to)686-696
Number of pages11
JournalClinical Advances in Hematology and Oncology
Volume17
Issue number12
StatePublished - Dec 2019
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Recurrence
Therapeutics
Interferons
Clinical Trials
Practice Guidelines
Patient Selection
Leukemia
Stem Cells
Clone Cells
Costs and Cost Analysis
Polymerase Chain Reaction
Survival
Population

Keywords

  • Chronic myeloid leukemia
  • Deep molecular response
  • Treatment-free remission
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Molica, M., Naqvi, K., Cortes, J. E., Paul, S., Kadia, T. M., Breccia, M., ... Jabbour, E. J. (2019). Treatment-free remission in chronic myeloid leukemia. Clinical Advances in Hematology and Oncology, 17(12), 686-696.

Treatment-free remission in chronic myeloid leukemia. / Molica, Matteo; Naqvi, Kiran; Cortes, Jorge E.; Paul, Shilpa; Kadia, Tapan M.; Breccia, Massimo; Kantarjian, Hagop; Jabbour, Elias J.

In: Clinical Advances in Hematology and Oncology, Vol. 17, No. 12, 12.2019, p. 686-696.

Research output: Contribution to journalArticle

Molica, M, Naqvi, K, Cortes, JE, Paul, S, Kadia, TM, Breccia, M, Kantarjian, H & Jabbour, EJ 2019, 'Treatment-free remission in chronic myeloid leukemia', Clinical Advances in Hematology and Oncology, vol. 17, no. 12, pp. 686-696.
Molica M, Naqvi K, Cortes JE, Paul S, Kadia TM, Breccia M et al. Treatment-free remission in chronic myeloid leukemia. Clinical Advances in Hematology and Oncology. 2019 Dec;17(12):686-696.
Molica, Matteo ; Naqvi, Kiran ; Cortes, Jorge E. ; Paul, Shilpa ; Kadia, Tapan M. ; Breccia, Massimo ; Kantarjian, Hagop ; Jabbour, Elias J. / Treatment-free remission in chronic myeloid leukemia. In: Clinical Advances in Hematology and Oncology. 2019 ; Vol. 17, No. 12. pp. 686-696.
@article{b919b208edbd4b829d288570b0163470,
title = "Treatment-free remission in chronic myeloid leukemia",
abstract = "Tyrosine kinase inhibitors (TKIs) represent a major breakthrough in the treatment of chronic myeloid leukemia (CML). Thanks to these agents, CML has been transformed from a disease with limited treatment options and a dismal prognosis into a more indolent disease with survival comparable to that of the general population. The need for ongoing TKI therapy remains controversial for several reasons, including cost and toxicity. Studies in CML patients with a sustained deep molecular response have demonstrated that stopping TKI therapy is feasible and safe. Given the heterogeneity of results reported in clinical trials, practice guidelines for optimal patient selection and proper monitoring after discontinuation of TKIs are proposed outside of clinical trials. Current data available show that 40{\%} to 60{\%} of patients who stop therapy relapse; molecular relapses typically occur within 6 months, but nearly all relapsing patients regain response upon reinitiation of the TKI. Several factors that predict for relapse have been investigated. Duration of prior TKI therapy, achievement of deep molecular response, depth of molecular response, prior interferon treatment, and Sokal risk score have been shown to be potential predictors for relapse. Leukemia stem cells that are resistant to TKIs, and that persist despite undetectable BCR/ ABL1 transcript levels, likely are responsible for disease relapse after discontinuation. Efforts geared toward better identification of low levels of BCR/ABL1 transcript using new techniques such as digital polymerase chain reaction, along with eradicating CML clones using combination therapies with agents such as pegylated interferon or venetoclax with TKIs, will hopefully lead to a functional cure of this disease.",
keywords = "Chronic myeloid leukemia, Deep molecular response, Treatment-free remission, Tyrosine kinase inhibitors",
author = "Matteo Molica and Kiran Naqvi and Cortes, {Jorge E.} and Shilpa Paul and Kadia, {Tapan M.} and Massimo Breccia and Hagop Kantarjian and Jabbour, {Elias J.}",
year = "2019",
month = "12",
language = "English (US)",
volume = "17",
pages = "686--696",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "12",

}

TY - JOUR

T1 - Treatment-free remission in chronic myeloid leukemia

AU - Molica, Matteo

AU - Naqvi, Kiran

AU - Cortes, Jorge E.

AU - Paul, Shilpa

AU - Kadia, Tapan M.

AU - Breccia, Massimo

AU - Kantarjian, Hagop

AU - Jabbour, Elias J.

PY - 2019/12

Y1 - 2019/12

N2 - Tyrosine kinase inhibitors (TKIs) represent a major breakthrough in the treatment of chronic myeloid leukemia (CML). Thanks to these agents, CML has been transformed from a disease with limited treatment options and a dismal prognosis into a more indolent disease with survival comparable to that of the general population. The need for ongoing TKI therapy remains controversial for several reasons, including cost and toxicity. Studies in CML patients with a sustained deep molecular response have demonstrated that stopping TKI therapy is feasible and safe. Given the heterogeneity of results reported in clinical trials, practice guidelines for optimal patient selection and proper monitoring after discontinuation of TKIs are proposed outside of clinical trials. Current data available show that 40% to 60% of patients who stop therapy relapse; molecular relapses typically occur within 6 months, but nearly all relapsing patients regain response upon reinitiation of the TKI. Several factors that predict for relapse have been investigated. Duration of prior TKI therapy, achievement of deep molecular response, depth of molecular response, prior interferon treatment, and Sokal risk score have been shown to be potential predictors for relapse. Leukemia stem cells that are resistant to TKIs, and that persist despite undetectable BCR/ ABL1 transcript levels, likely are responsible for disease relapse after discontinuation. Efforts geared toward better identification of low levels of BCR/ABL1 transcript using new techniques such as digital polymerase chain reaction, along with eradicating CML clones using combination therapies with agents such as pegylated interferon or venetoclax with TKIs, will hopefully lead to a functional cure of this disease.

AB - Tyrosine kinase inhibitors (TKIs) represent a major breakthrough in the treatment of chronic myeloid leukemia (CML). Thanks to these agents, CML has been transformed from a disease with limited treatment options and a dismal prognosis into a more indolent disease with survival comparable to that of the general population. The need for ongoing TKI therapy remains controversial for several reasons, including cost and toxicity. Studies in CML patients with a sustained deep molecular response have demonstrated that stopping TKI therapy is feasible and safe. Given the heterogeneity of results reported in clinical trials, practice guidelines for optimal patient selection and proper monitoring after discontinuation of TKIs are proposed outside of clinical trials. Current data available show that 40% to 60% of patients who stop therapy relapse; molecular relapses typically occur within 6 months, but nearly all relapsing patients regain response upon reinitiation of the TKI. Several factors that predict for relapse have been investigated. Duration of prior TKI therapy, achievement of deep molecular response, depth of molecular response, prior interferon treatment, and Sokal risk score have been shown to be potential predictors for relapse. Leukemia stem cells that are resistant to TKIs, and that persist despite undetectable BCR/ ABL1 transcript levels, likely are responsible for disease relapse after discontinuation. Efforts geared toward better identification of low levels of BCR/ABL1 transcript using new techniques such as digital polymerase chain reaction, along with eradicating CML clones using combination therapies with agents such as pegylated interferon or venetoclax with TKIs, will hopefully lead to a functional cure of this disease.

KW - Chronic myeloid leukemia

KW - Deep molecular response

KW - Treatment-free remission

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85076945651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076945651&partnerID=8YFLogxK

M3 - Article

C2 - 31851157

AN - SCOPUS:85076945651

VL - 17

SP - 686

EP - 696

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 12

ER -